|
|
 Re: Kassenpatient Nr. 1 Das deutsche Gesundheitssystem (Re: محمد بدوي مصطفى)
|
Cash Patient No. 1 The German health system
May 6th, 2011 | Category: Germany, News
New and old problems at a glance
Martin Smolorz
Going to the pharmacy or the doctor has fallen in recent days in most patients particularly difficult. Not least by the new health reform, which has it in particular to the pockets of insured patients. Early as 1 January, may require any cash from the insured any greater additional contributions. In return, a social compensation for financially weak SHI members is provided that is modeled on the "average additional contribution." However, the Federal Ministry of Health, already fixed on 03.01.2011 the "average additional contribution" to zero euros. As a result of this regime can not make a low-social compensation claims. Thus remains the only instance of protection of the insured, the clouded hope of the free competition, which will hold the additional premiums at a low price level. Particularly promising in this way seems not to be there already existed in 2010 a strong suspicion of price collusion in the case of new health insurance of the Federal Government.
In view of the health policy of unilateral Mr. Roesler, which breaks the social compensation further, especially the pharmaceutical companies are reputed to pursue price gouging. By international comparison, the German funds for the same preparations, often pay three times the normal market price. This discrepancy is due to the lack of a body back to that prescribed in the German market, the pharmaceutical companies a justified and reasonable price for the offered products. That should change with the laced firmly savings package of the federal government and force the pharmaceutical manufacturers for joint pricing agreements with the funds, by threat of force reductions. Likewise, the Institute for Quality and Efficiency in Health Care (IQWiG) clear the jungle of drugs every year flood the drug market. According to Juergen Windler, head of the recently established (IQWiG), most new drugs are redundant, so that only ten percent of all products are really useful.
Much will probably still remain the same. As stated many years ago of Transparency International, the German health care from corruption is not filed. According to Transparency annual cash contributions disappear worth several billion euros in the thicket of unfair competition and nepotism. These accusations were directed increasingly against the doctors who prescribe more expensive drugs to consumers. Throughout the debate on the blame, see Dieter Reiber, Director of the Institute for Interdisciplinary Biological Research (IBF), the local medical profession as just pawns. "Often the fish begins to stink from the head."
When last did in the newspaper, among the advertisements, stood a vacancy as a cash management board? In most cases, the site of a large cash functionary is governed by agreements with the pharmaceutical lobby to also receive future the price monopoly upright.
How fluent are now the borders between power providers and service providers, the example shows the top-Barmer-boss Birgit Fischer, who after many years as a board leader of the largest providers of statutory health insurance in Germany, in the drug squad of the Association of Research-Based Pharmaceutical Manufacturers Association ( VFA changed). Even incumbent CDU members, such as the health expert Jens Spahn doubt on the honesty of the SPD politician.
Many of the problems are homemade, for the most part and have already been resolved satisfactorily in the past by any coalition. What course the health care strike in the future is to be seen, first, because only the federal election could bring in 29 months, a possible turning point.
----
translation from google!
| |
 
|
|
|
|
محمد بدوي مصطفى
بدر الدين احمد موسى
فيس بوك
تويتر
انستقرام
يوتيوب
بنتيريست